Brief: Cytodyn Provides Update On Dose Escalating Trial With Leronlimab For Hiv Monotherapy For A Potential Pivotal Trial
14/08/2019 13:16
Aug 14 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN PROVIDES UPDATE ON DOSE ESCALATING TRIAL WITH
LERONLIMAB
FOR HIV MONOTHERAPY FOR A POTENTIAL PIVOTAL TRIAL
* CYTODYN INC - RESPONSE RATE POST-10 WEEKS OF MONOTHERAPY
IS 68%
WITH 350 MG DOSE, 94% WITH 525 MG AND 85% WITH 700 MG
Source text for Eikon: ID:nGNXkSbly
Further company coverage: CYDY.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer